Double Versus Standard Loading Dose of Ticagrelor: Onset of Antiplatelet Action in Patients With STEMI Undergoing Primary PCI | Journal of the American College of Cardiology
Brilinta (Ticagrelor Tablets for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
Ticagrelor Dosage Guide + Max Dose, Adjustments - Drugs.com
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week - ScienceDirect
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI - ScienceDirect
Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study | BMC Cardiovascular Disorders
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI - ScienceDirect
JCM | Free Full-Text | De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature | HTML
2 3 De escalation strategies
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention - ScienceDirect
Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial | Journal of the American Heart Association
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention - American Journal of Cardiology
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Antiplatelet therapy in coronary artery disease
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome - STEPS - American Family Physician
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | tctmd.com
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health - Journal of Cardiology
Dosing & Administration | BRILINTA® (ticagrelor) tablets | For HCPs
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4 | tctmd.com
